On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer samples into high-resolution, multimodal datasets, backed by £18.9 million in ...

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. 10x Genomics is collaborating with PharosAI and leading UK institutions to build ...

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ ...

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region ASTRA will bring together molecular and spatial data ...

PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS) ...

After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...

New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput "Seeing the Xenium Prime 5K data reminded me of the ...

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region The Garvan Institute of Medical Research brings together ...